Clinical efficacy of medroxyprogesterone acetate combined with chemotherapy in the treatment of patients with endometrial carcinoma after surgery
Objective To explore the clinical efficacy of medroxyprogesterone acetate combined with chemotherapy in the treatment of patients with endometrial carcinoma after surgery.Method A total of 98 patients with endometrial carcinoma were divided into control group(n=49,chemotherapy alone)and observation group(n=49,medroxyprogester-one acetate combined with chemotherapy)according to the different treatment methods after laparoscopic surgery.The tu-mor markers[tumor specific growth factor(TSGF),X-linked inhibitor of apoptosis(XIAP),tumor necrosis factor-α(TNF-α)]levels,sex hormones[estradiol(E2),testosterone(T),follicle stimulating hormone(FSH),luteinizing hormone(LH),prolactin(PRL)and sex hormone-binding globulin(SHBG)]levels,quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)],adverse reactions,recurrence rate and recurrence interval were compared between the two groups.Result After treatment,the TSGF,XIAP,TNF-α and E2 lev-els in both groups were lower than those before treatment,and the TSGF,XIAP,TNF-α and E2 levels in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treat-ment,the scores of cognitive function,physical function,emotional function and social function in both groups were high-er than those before treatment,and the scores of cognitive function,physical function,emotional function and social func-tion in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).There were no significant differences in the incidence of myelosuppression,gastrointestinal reaction and abnor-mal liver and kidney function between the two groups(P>0.05).After 6 months of follow-up,the recurrence rate of the observation group was lower than that of the control group,and the recurrence interval was longer than that of the control group,and the differences were statistically significant(P<0.05).Conclusion Medroxyprogesterone acetate combined with chemotherapy in the treatment of patients with endometrial carcinoma after surgery has good clinical efficacy,which can reduce the levels of tumor markers and recurrence rate,improve the quality of life and has high safety.
endometrial carcinomamedroxyprogesterone acetatechemotherapytumor markerquality of lifere-currence
NETL
NSTL
万方数据
